MAP2K7 and uveal melanoma: This was the first study to assess the intermittent administration of MEK inhibition in patients with metastatic uveal melanoma and was based on preclinical data which identified MEK inhibition as a viable target in uveal melanoma as well as clinical trial data which demonstrated limited benefit with continuous MEK inhibition.